Decreased salivary lactoferrin levels are specific to Alzheimer's disease.

Aged Alzheimer Disease / diagnosis Amyloid beta-Peptides / genetics Biomarkers / metabolism Brain / diagnostic imaging Cognitive Dysfunction / genetics Female Humans Immunity, Innate / genetics Lactoferrin / genetics Male Middle Aged Neuroimaging / methods Positron-Emission Tomography / methods Salivary Glands / metabolism Tomography, X-Ray Computed tau Proteins / genetics
Alzheimer´s disease Biomarkers Frontotemporal dementia Lactoferrin Pet imaging Saliva

Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 16 04 2020
revised: 15 05 2020
accepted: 29 05 2020
pubmed: 27 6 2020
medline: 26 5 2021
entrez: 27 6 2020
Statut: ppublish

Résumé

Evidences of infectious pathogens in Alzheimer's disease (AD) brains may suggest a deteriorated innate immune system in AD pathophysiology. We previously demonstrated reduced salivary lactoferrin (Lf) levels, one of the major antimicrobial proteins, in AD patients. To assess the clinical utility of salivary Lf for AD diagnosis, we examine the relationship between salivary Lf and cerebral amyloid-β (Aβ) load using amyloid-Positron-Emission Tomography (PET) neuroimaging, in two different cross-sectional cohorts including patients with different neurodegenerative disorders. The diagnostic performance of salivary Lf in the cohort 1 had an area under the curve [AUC] of 0•95 (0•911-0•992) for the differentiation of the prodromal AD/AD group positive for amyloid-PET (PET Salivary Lf seems to have a very good diagnostic performance to detect AD. Our findings support the possible utility of salivary Lf as a new non-invasive and cost-effective AD biomarker. Instituto de Salud Carlos III (FIS15/00780, FIS18/00118), FEDER, Comunidad de Madrid (S2017/BMD-3700; NEUROMETAB-CM), and CIBERNED (PI2016/01) to E.C.; Spanish Ministry of Economy and Competitiveness (SAF2017-85310-R) to J.L.C., and (PSI2017-85311-P) to M.A.; International Centre on ageing CENIE-POCTEP (0348_CIE_6_E) to M.A.; Instituto de Salud Carlos III (PIE16/00021, PI17/01799), to H.B.

Sections du résumé

BACKGROUND BACKGROUND
Evidences of infectious pathogens in Alzheimer's disease (AD) brains may suggest a deteriorated innate immune system in AD pathophysiology. We previously demonstrated reduced salivary lactoferrin (Lf) levels, one of the major antimicrobial proteins, in AD patients.
METHODS METHODS
To assess the clinical utility of salivary Lf for AD diagnosis, we examine the relationship between salivary Lf and cerebral amyloid-β (Aβ) load using amyloid-Positron-Emission Tomography (PET) neuroimaging, in two different cross-sectional cohorts including patients with different neurodegenerative disorders.
FINDINGS RESULTS
The diagnostic performance of salivary Lf in the cohort 1 had an area under the curve [AUC] of 0•95 (0•911-0•992) for the differentiation of the prodromal AD/AD group positive for amyloid-PET (PET
INTERPRETATION CONCLUSIONS
Salivary Lf seems to have a very good diagnostic performance to detect AD. Our findings support the possible utility of salivary Lf as a new non-invasive and cost-effective AD biomarker.
FUNDING BACKGROUND
Instituto de Salud Carlos III (FIS15/00780, FIS18/00118), FEDER, Comunidad de Madrid (S2017/BMD-3700; NEUROMETAB-CM), and CIBERNED (PI2016/01) to E.C.; Spanish Ministry of Economy and Competitiveness (SAF2017-85310-R) to J.L.C., and (PSI2017-85311-P) to M.A.; International Centre on ageing CENIE-POCTEP (0348_CIE_6_E) to M.A.; Instituto de Salud Carlos III (PIE16/00021, PI17/01799), to H.B.

Identifiants

DOI: 10.1016/j.ebiom.2020.102834 PMID: 32586758 PMC: PMC7378957
pubmed: 32586758
pii: S2352-3964(20)30209-7
doi: 10.1016/j.ebiom.2020.102834
pmc: PMC7378957
pii:
doi:

Substances chimiques

Amyloid beta-Peptides 0
Biomarkers 0
tau Proteins 0
Lactoferrin EC 3.4.21.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102834

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Références

Alzheimers Dement (Amst). 2017 May 26;8:131-138
pubmed: 28649597
J Neuroinflammation. 2012 Jul 02;9:151
pubmed: 22747753
Lancet. 1997 Jan 25;349(9047):241-4
pubmed: 9014911
Neuron. 2018 Jul 11;99(1):56-63.e3
pubmed: 30001512
Int J Mol Sci. 2017 Sep 15;18(9):
pubmed: 28914813
Neurobiol Aging. 2018 Feb;62:45-52
pubmed: 29107846
Nutr Res. 2008 Sep;28(9):583-9
pubmed: 19083463
Oral Microbiol Immunol. 2009 Oct;24(5):411-6
pubmed: 19702956
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Nat Immunol. 2015 Mar;16(3):229-36
pubmed: 25689443
Lancet Neurol. 2012 Aug;11(8):669-78
pubmed: 22749065
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Sci Rep. 2015 Jun 02;5:10729
pubmed: 26035688
Neuron. 2018 Jul 11;99(1):64-82.e7
pubmed: 29937276
J Periodontol. 2008 Dec;79(12):2233-40
pubmed: 19053911
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
Neuropsychopharmacology. 2017 Dec;42(13):2504-2515
pubmed: 28079060
Alzheimers Dement. 2015 Jun;11(6):593-9
pubmed: 25043910
Eur J Hum Genet. 2002 Jul;10(7):399-405
pubmed: 12107813
Biometals. 2004 Jun;17(3):209-16
pubmed: 15222467
Biomed Pharmacother. 2019 Mar;111:714-723
pubmed: 30611996
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Redox Biol. 2019 Feb;21:101090
pubmed: 30593976
Alzheimers Dement. 2015 Jan;11(1):51-7
pubmed: 24637300
Neurobiol Aging. 2004 May-Jun;25(5):619-27
pubmed: 15172740
Neurobiol Aging. 2018 Mar;63:12-21
pubmed: 29207277
Front Aging Neurosci. 2014 Aug 11;6:202
pubmed: 25157230
Biometals. 2004 Jun;17(3):189-96
pubmed: 15222464
J Appl Microbiol. 2010 Oct;109(4):1311-8
pubmed: 20477900
J Mol Neurosci. 2016 Nov;60(3):316-324
pubmed: 27498201
Alzheimers Dement. 2011 May;7(3):257-62
pubmed: 21514247
Front Genet. 2018 Sep 10;9:362
pubmed: 30250480
Ann Neurol. 2010 Sep;68(3):319-29
pubmed: 20687209
Alzheimers Dement. 2015 Jun;11(6):587-92
pubmed: 25304990
Biochim Biophys Acta Mol Basis Dis. 2018 Jan;1864(1):263-273
pubmed: 29107091
J Periodontol. 2001 Jan;72(1):90-5
pubmed: 11210079
Ann Neurol. 2011 Feb;69(2):312-9
pubmed: 21387376
Sci Adv. 2019 Jan 23;5(1):eaau3333
pubmed: 30746447
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
J Neuropathol Exp Neurol. 2006 Jul;65(7):631-41
pubmed: 16825950
Cell Metab. 2015 Nov 3;22(5):761-76
pubmed: 26365177
J Biol Chem. 2013 Nov 1;288(44):31655-69
pubmed: 24036113
Neurosci Lett. 2009 Mar 20;452(3):277-80
pubmed: 19348738
Lancet Neurol. 2011 May;10(5):424-35
pubmed: 21481640
Nat Rev Immunol. 2014 Jul;14(7):463-77
pubmed: 24962261
Auton Neurosci. 2007 Apr 30;133(1):3-18
pubmed: 17157080
PLoS One. 2018 Oct 3;13(10):e0204941
pubmed: 30281647
Eur J Appl Physiol. 2015 Sep;115(9):1887-95
pubmed: 25893563
Mol Pharmacol. 2013 Dec;84(6):888-98
pubmed: 24077968
Cell Mol Life Sci. 2005 Nov;62(22):2576-87
pubmed: 16261253
Eur J Appl Physiol. 2016 Jun;116(6):1219-29
pubmed: 27129582
PLoS One. 2011;6(7):e22504
pubmed: 21799877
Alzheimers Dement. 2020 Aug;16(8):1196-1204
pubmed: 32543760
Cell Mol Life Sci. 2005 Nov;62(22):2588-98
pubmed: 16261252
Front Aging Neurosci. 2014 Jun 16;6:127
pubmed: 24982633
J Immunol. 2008 Jul 1;181(1):712-20
pubmed: 18566438
BMC Neurol. 2015 Aug 20;15:146
pubmed: 26289075
Biosci Biotechnol Biochem. 2017 Jul;81(7):1300-1304
pubmed: 28351211
J Neuroinflammation. 2011 Aug 04;8:90
pubmed: 21816039
Prog Neurobiol. 1997 Feb;51(2):195-222
pubmed: 9247964
J Intern Med. 2004 Sep;256(3):240-6
pubmed: 15324367
J Strength Cond Res. 2015 May;29(5):1359-66
pubmed: 25915527
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
J Alzheimers Dis. 2008 May;13(4):437-49
pubmed: 18487851
Molecules. 2011 Aug 16;16(8):6992-7018
pubmed: 21847071
Neurodegener Dis Manag. 2016 Oct;6(5):345-8
pubmed: 27599536
Biometals. 2018 Jun;31(3):425-443
pubmed: 29748743
J Alzheimers Dis. 2017;58(4):1303-1313
pubmed: 28582858
Auton Neurosci. 2017 Dec;208:15-28
pubmed: 28918243
Am J Pathol. 1993 May;142(5):1574-85
pubmed: 8494052
Am J Alzheimers Dis Other Demen. 2015 Aug;30(5):478-87
pubmed: 25380804
J Alzheimers Dis. 2016;51(4):979-84
pubmed: 26967229

Auteurs

Marta González-Sánchez (M)

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; Neurology Service Hospital Universitario 12 de Octubre, Madrid, Spain.

Fernando Bartolome (F)

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain. Electronic address: fbartolome.imas12@h12o.es.

Desiree Antequera (D)

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain.

Veronica Puertas-Martín (V)

Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; CIBER de Enfermedades Cardiovasculares, Madrid, Spain; Hospital Universitario 12 de Octubre Research Institute (imas12), Madrid, Spain.

Pilar González (P)

Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; CIBER de Enfermedades Cardiovasculares, Madrid, Spain; Hospital Universitario 12 de Octubre Research Institute (imas12), Madrid, Spain.

Adolfo Gómez-Grande (A)

Nuclear Medicine Service, Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain.

Sara Llamas-Velasco (S)

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; Neurology Service Hospital Universitario 12 de Octubre, Madrid, Spain.

Alejandro Herrero-San Martín (A)

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; Neurology Service Hospital Universitario 12 de Octubre, Madrid, Spain.

David Pérez-Martínez (D)

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; Neurology Service Hospital Universitario 12 de Octubre, Madrid, Spain.

Alberto Villarejo-Galende (A)

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain; Neurology Service Hospital Universitario 12 de Octubre, Madrid, Spain.

Mercedes Atienza (M)

Laboratory of Functional Neuroscience, Pablo de Olavide University, Seville, Spain, CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Spain.

Miriam Palomar-Bonet (M)

Laboratory of Functional Neuroscience, Pablo de Olavide University, Seville, Spain, CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Spain.

Jose Luis Cantero (JL)

Laboratory of Functional Neuroscience, Pablo de Olavide University, Seville, Spain, CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Spain.

George Perry (G)

Department of Biology and Neurosciences Institute, University of Texas at San Antonio, San Antonio, TX, USA.

Gorka Orive (G)

Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria, Spain; Networked Center for Biomedical Research in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain.

Borja Ibañez (B)

Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain, CIBER de Enfermedades Cardiovasculares, Madrid, Spain; IIS-Fundacion Jiménez Díaz Hospital, Madrid, Spain.

Hector Bueno (H)

Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain, CIBER de Enfermedades Cardiovasculares, Madrid, Spain; Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain; Hospital Universitario 12 de Octubre Research Institute (imas12), Cardiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.

Valentin Fuster (V)

Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; Icahn School of Medicine at Mount Sinai, New York, New York, United States.

Eva Carro (E)

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain. Electronic address: carroeva@h12o.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Decreased salivary lactoferrin levels are...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Decreased salivary lactoferrin levels are...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Peptides bêta-amyloïdes › Decreased salivary lactoferrin levels are...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Decreased salivary lactoferrin levels are...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Decreased salivary lactoferrin levels are...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Troubles de la cognition › Dysfonctionnement cognitif › Decreased salivary lactoferrin levels are...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Decreased salivary lactoferrin levels are...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité innée › Decreased salivary lactoferrin levels are...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Métalloprotéines › Protéines de liaison au fer › Transferrines › Lactoferrine › Decreased salivary lactoferrin levels are...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Decreased salivary lactoferrin levels are...
questionsmedicales.fr › Techniques d'investigation › Neuroimagerie › Decreased salivary lactoferrin levels are...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Decreased salivary lactoferrin levels are...
questionsmedicales.fr › Système stomatognathique › Bouche › Glandes salivaires › Decreased salivary lactoferrin levels are...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Tomographie à rayons X › Tomodensitométrie › Decreased salivary lactoferrin levels are...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Protéines associées aux microtubules › Protéines tau › Decreased salivary lactoferrin levels are...